Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Abbott launched an over-the-counter continuous glucose monitoring system, Lingo, for adults not on insulin -- the second such ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

DexCom ( DXCM -2.62%) is not a stock that investors should be rushing to sell. It has a few different opportunities to ...

The Food and Drug Administration cleared Abbott’s Freestyle Libre 2 and 3 for integration with AID systems in March 2023. Earlier this year, Abbott integrated its FreeStyle Libre 2 Plus sensor with ...

Abbott introduced a revolutionary new device, FreeStyle Navigator, designed to improve the lives of the world’s more than 500 million diabetes patients by offering continuous glucose monitoring with ...

Abbott has announced the U.S. availability of Lingo, the company’s first glucose monitoring system available without ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

Abbott ABT is facing a challenging business environment globally. Unfavorable foreign exchange impact continues to impede ...

Abbott's strong innovation pipeline, including advancements in CGM systems, supports its market share gains and growth ...

The episode was not found or is unavailable. In this bonus episode Emma speaks to Dawn Adams, a midwife and menopause ...